Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786417 · ClinicalTrials.gov registry record · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
A Phase 4 study of Angina and Stable Ischemic Heart Disease, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 741
- Enrollment target
- 9
- Study locations
NCT05786417: Recruiting Phase 4 study of Angina and Stable Ischemic Heart Disease, sponsored by Yale University.
NCT05786417 is a Phase 4 study of Angina and Stable Ischemic Heart Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 741 participants, below the 10,505-participant average among 4 other Angina trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05786417, a Phase 4 study of Angina and Stable Ischemic Heart Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 741 participants
- Enrollment target
- 9
- Study locations
Study Summary
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Primary Outcome
The EQ-5D-5L represents a global quality of life measure that includes multiple components potentially impacted by the anti-anginal treatments being examined. The EQ-5D-5L score includes questions on mobility, self-care, usual activities, anxiety/depression, and pain/discomfort on a 5-point scale: 1=No Problem, 2=Slight Problem, 3=Moderate Problem, 4=Severe Problem, 5=Extreme Problem or Inability. 0, 1, and negative values corresponding to death, full health, and health states worse than death,
Conditions Studied
Interventions
- DRUG Beta blocker
- OTHER Clinician Discretion
- DRUG Calcium channel blocker
Study Locations (9)
New York
- Mt. Sinai Health System - New York
- NYC Health and Hospitals, Harlem Hospital - New York
- Nirvana Integrative Medicine - New York
Connecticut
- Yale School of Medicine - New Haven
Georgia
- Wellstar Research Institute - Marietta
Illinois
- Cook County Health - Chicago
Massachusetts
- Brigham and Women's Hospital - Boston
North Carolina
- Duke University, School of Medicine - Durham
Virginia
- Inova Health Care Services - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2027-05-30 |
| Phase | Phase 4 |
What NCT05786417 shows while recruiting
NCT05786417 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, below the 10,505-participant average among 4 other Angina trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Angina appearing as the primary indexed condition, and to 3 interventions - of which Beta blocker is the first listed.
NCT05786417 lists 9 locations in 7 states (New York, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT05786417 about?
NCT05786417 is a clinical study titled "LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions". To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
What is the current status of trial NCT05786417?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 741 participants. The study started on 2023-05-10. Estimated completion is 2027-05-30.
What conditions does trial NCT05786417 study?
This clinical trial studies the following conditions: Angina, Stable Ischemic Heart Disease.
What interventions are being tested in trial NCT05786417?
The interventions under investigation include: Beta blocker (DRUG), Clinician Discretion (OTHER), Calcium channel blocker (DRUG).
Who is sponsoring clinical trial NCT05786417?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05786417 being conducted?
This trial has 9 study locations across Connecticut, Georgia, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angina
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Coronary Microvascular Dysfunction (CMD) Study
RECRUITING · NA
-
An Observational Study of Cholesterol in Coronary Arteries
COMPLETED
-
Improving Service Delivery Through Access Points
COMPLETED
-
Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI